NOVARTIS AG-REG (NOT.DE) Fundamental Analysis & Valuation

FRA:NOT • CH0012005267

Current stock price

129.08 EUR
+1.84 (+1.45%)
Last:

This NOT.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. NOT.DE Profitability Analysis

1.1 Basic Checks

  • NOT had positive earnings in the past year.
  • In the past year NOT had a positive cash flow from operations.
  • In the past 5 years NOT has always been profitable.
  • In the past 5 years NOT always reported a positive cash flow from operatings.
NOT.DE Yearly Net Income VS EBIT VS OCF VS FCFNOT.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B

1.2 Ratios

  • NOT has a Return On Assets of 12.60%. This is amongst the best in the industry. NOT outperforms 80.39% of its industry peers.
  • NOT's Return On Equity of 30.31% is fine compared to the rest of the industry. NOT outperforms 78.43% of its industry peers.
  • NOT has a Return On Invested Capital of 19.32%. This is amongst the best in the industry. NOT outperforms 80.39% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for NOT is above the industry average of 13.99%.
  • The 3 year average ROIC (17.15%) for NOT is below the current ROIC(19.32%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.6%
ROE 30.31%
ROIC 19.32%
ROA(3y)13.05%
ROA(5y)12.66%
ROE(3y)29.75%
ROE(5y)27.29%
ROIC(3y)17.15%
ROIC(5y)14%
NOT.DE Yearly ROA, ROE, ROICNOT.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • NOT's Profit Margin of 24.83% is amongst the best of the industry. NOT outperforms 86.27% of its industry peers.
  • In the last couple of years the Profit Margin of NOT has grown nicely.
  • Looking at the Operating Margin, with a value of 33.18%, NOT belongs to the top of the industry, outperforming 84.31% of the companies in the same industry.
  • In the last couple of years the Operating Margin of NOT has grown nicely.
  • NOT has a better Gross Margin (75.82%) than 78.43% of its industry peers.
  • NOT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 33.18%
PM (TTM) 24.83%
GM 75.82%
OM growth 3Y12.14%
OM growth 5Y6.09%
PM growth 3Y15.69%
PM growth 5Y8.94%
GM growth 3Y0.74%
GM growth 5Y1.28%
NOT.DE Yearly Profit, Operating, Gross MarginsNOT.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. NOT.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NOT is creating value.
  • Compared to 1 year ago, NOT has less shares outstanding
  • Compared to 5 years ago, NOT has less shares outstanding
  • NOT has a worse debt/assets ratio than last year.
NOT.DE Yearly Shares OutstandingNOT.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B
NOT.DE Yearly Total Debt VS Total AssetsNOT.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B

2.2 Solvency

  • NOT has an Altman-Z score of 4.54. This indicates that NOT is financially healthy and has little risk of bankruptcy at the moment.
  • NOT's Altman-Z score of 4.54 is fine compared to the rest of the industry. NOT outperforms 66.67% of its industry peers.
  • The Debt to FCF ratio of NOT is 2.32, which is a good value as it means it would take NOT, 2.32 years of fcf income to pay off all of its debts.
  • NOT has a better Debt to FCF ratio (2.32) than 76.47% of its industry peers.
  • NOT has a Debt/Equity ratio of 0.64. This is a neutral value indicating NOT is somewhat dependend on debt financing.
  • NOT has a Debt to Equity ratio (0.64) which is in line with its industry peers.
  • Even though the debt/equity ratio score it not favorable for NOT, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF 2.32
Altman-Z 4.54
ROIC/WACC3.99
WACC4.84%
NOT.DE Yearly LT Debt VS Equity VS FCFNOT.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B

2.3 Liquidity

  • NOT has a Current Ratio of 1.12. This is a normal value and indicates that NOT is financially healthy and should not expect problems in meeting its short term obligations.
  • NOT has a Current ratio (1.12) which is in line with its industry peers.
  • NOT has a Quick Ratio of 1.12. This is a bad value and indicates that NOT is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.89, NOT perfoms like the industry average, outperforming 43.14% of the companies in the same industry.
  • NOT does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 0.89
NOT.DE Yearly Current Assets VS Current LiabilitesNOT.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. NOT.DE Growth Analysis

3.1 Past

  • NOT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.98%, which is quite good.
  • NOT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.21% yearly.
  • NOT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.91%.
  • The Revenue has been growing slightly by 2.45% on average over the past years.
EPS 1Y (TTM)14.98%
EPS 3Y13.63%
EPS 5Y9.21%
EPS Q2Q%2.53%
Revenue 1Y (TTM)8.91%
Revenue growth 3Y9.1%
Revenue growth 5Y2.45%
Sales Q2Q%1.39%

3.2 Future

  • Based on estimates for the next years, NOT will show a small growth in Earnings Per Share. The EPS will grow by 7.48% on average per year.
  • NOT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.99% yearly.
EPS Next Y-0.14%
EPS Next 2Y4.63%
EPS Next 3Y6.15%
EPS Next 5Y7.48%
Revenue Next Year2.49%
Revenue Next 2Y3.87%
Revenue Next 3Y4.58%
Revenue Next 5Y4.99%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NOT.DE Yearly Revenue VS EstimatesNOT.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B
NOT.DE Yearly EPS VS EstimatesNOT.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

5

4. NOT.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 16.96 indicates a correct valuation of NOT.
  • Based on the Price/Earnings ratio, NOT is valued a bit cheaper than the industry average as 62.75% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of NOT to the average of the S&P500 Index (27.87), we can say NOT is valued slightly cheaper.
  • With a Price/Forward Earnings ratio of 16.98, NOT is valued correctly.
  • NOT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NOT is cheaper than 62.75% of the companies in the same industry.
  • NOT's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 38.51.
Industry RankSector Rank
PE 16.96
Fwd PE 16.98
NOT.DE Price Earnings VS Forward Price EarningsNOT.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, NOT is valued a bit cheaper than the industry average as 60.78% of the companies are valued more expensively.
  • 62.75% of the companies in the same industry are more expensive than NOT, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 20.33
EV/EBITDA 13.89
NOT.DE Per share dataNOT.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • NOT has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.84
EPS Next 2Y4.63%
EPS Next 3Y6.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. NOT.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 3.15%, NOT has a reasonable but not impressive dividend return.
  • NOT's Dividend Yield is a higher than the industry average which is at 1.94.
  • NOT's Dividend Yield is rather good when compared to the S&P500 average which is at 1.81.
Industry RankSector Rank
Dividend Yield 3.15%

5.2 History

  • The dividend of NOT has a limited annual growth rate of 5.38%.
Dividend Growth(5Y)5.38%
Div Incr Years1
Div Non Decr Years1
NOT.DE Yearly Dividends per shareNOT.DE Yearly Dividends per shareYearly Dividends per share 2019 2025 2026 1 2 3

5.3 Sustainability

  • NOT pays out 55.91% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • NOT's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP55.91%
EPS Next 2Y4.63%
EPS Next 3Y6.15%
NOT.DE Yearly Income VS Free CF VS DividendNOT.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B
NOT.DE Dividend Payout.NOT.DE Dividend Payout, showing the Payout Ratio.NOT.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

NOT.DE Fundamentals: All Metrics, Ratios and Statistics

NOVARTIS AG-REG

FRA:NOT (4/17/2026, 7:00:00 PM)

129.08

+1.84 (+1.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04
Earnings (Next)04-28
Inst Owners43.85%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap262.65B
Revenue(TTM)56.33B
Net Income(TTM)13.98B
Analysts70.59
Price Target137.82 (6.77%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.15%
Yearly Dividend3.4
Dividend Growth(5Y)5.38%
DP55.91%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.14%
Min EPS beat(2)-2.1%
Max EPS beat(2)-0.17%
EPS beat(4)2
Avg EPS beat(4)1.23%
Min EPS beat(4)-2.1%
Max EPS beat(4)6.59%
EPS beat(8)6
Avg EPS beat(8)2.93%
EPS beat(12)9
Avg EPS beat(12)2.91%
EPS beat(16)11
Avg EPS beat(16)2.66%
Revenue beat(2)0
Avg Revenue beat(2)-3.85%
Min Revenue beat(2)-4.89%
Max Revenue beat(2)-2.82%
Revenue beat(4)0
Avg Revenue beat(4)-2.92%
Min Revenue beat(4)-4.89%
Max Revenue beat(4)-1.13%
Revenue beat(8)4
Avg Revenue beat(8)-0.49%
Revenue beat(12)5
Avg Revenue beat(12)-2.7%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.01%
PT rev (3m)18.27%
EPS NQ rev (1m)1.12%
EPS NQ rev (3m)-4.31%
EPS NY rev (1m)-0.83%
EPS NY rev (3m)-3.86%
Revenue NQ rev (1m)0.69%
Revenue NQ rev (3m)-0.55%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)-0.21%
Valuation
Industry RankSector Rank
PE 16.96
Fwd PE 16.98
P/S 5.5
P/FCF 20.33
P/OCF 16.19
P/B 6.72
P/tB N/A
EV/EBITDA 13.89
EPS(TTM)7.61
EY5.9%
EPS(NY)7.6
Fwd EY5.89%
FCF(TTM)6.35
FCFY4.92%
OCF(TTM)7.98
OCFY6.18%
SpS23.47
BVpS19.22
TBVpS-3.69
PEG (NY)N/A
PEG (5Y)1.84
Graham Number57.3623 (-55.56%)
Profitability
Industry RankSector Rank
ROA 12.6%
ROE 30.31%
ROCE 22.34%
ROIC 19.32%
ROICexc 22.42%
ROICexgc 94.51%
OM 33.18%
PM (TTM) 24.83%
GM 75.82%
FCFM 27.06%
ROA(3y)13.05%
ROA(5y)12.66%
ROE(3y)29.75%
ROE(5y)27.29%
ROIC(3y)17.15%
ROIC(5y)14%
ROICexc(3y)20.47%
ROICexc(5y)17.14%
ROICexgc(3y)94.66%
ROICexgc(5y)84.88%
ROCE(3y)20.57%
ROCE(5y)16.8%
ROICexgc growth 3Y10.97%
ROICexgc growth 5Y16.26%
ROICexc growth 3Y23.26%
ROICexc growth 5Y13.82%
OM growth 3Y12.14%
OM growth 5Y6.09%
PM growth 3Y15.69%
PM growth 5Y8.94%
GM growth 3Y0.74%
GM growth 5Y1.28%
F-Score8
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF 2.32
Debt/EBITDA 1.23
Cap/Depr 73.24%
Cap/Sales 6.92%
Interest Coverage 19.05
Cash Conversion 79.71%
Profit Quality 109.01%
Current Ratio 1.12
Quick Ratio 0.89
Altman-Z 4.54
F-Score8
WACC4.84%
ROIC/WACC3.99
Cap/Depr(3y)63.14%
Cap/Depr(5y)55.05%
Cap/Sales(3y)6.73%
Cap/Sales(5y)6.62%
Profit Quality(3y)101.15%
Profit Quality(5y)104.02%
High Growth Momentum
Growth
EPS 1Y (TTM)14.98%
EPS 3Y13.63%
EPS 5Y9.21%
EPS Q2Q%2.53%
EPS Next Y-0.14%
EPS Next 2Y4.63%
EPS Next 3Y6.15%
EPS Next 5Y7.48%
Revenue 1Y (TTM)8.91%
Revenue growth 3Y9.1%
Revenue growth 5Y2.45%
Sales Q2Q%1.39%
Revenue Next Year2.49%
Revenue Next 2Y3.87%
Revenue Next 3Y4.58%
Revenue Next 5Y4.99%
EBIT growth 1Y14.46%
EBIT growth 3Y22.35%
EBIT growth 5Y8.7%
EBIT Next Year12.61%
EBIT Next 3Y8.86%
EBIT Next 5Y8.66%
FCF growth 1Y10.42%
FCF growth 3Y9.64%
FCF growth 5Y6.62%
OCF growth 1Y8.66%
OCF growth 3Y10.38%
OCF growth 5Y7%

NOVARTIS AG-REG / NOT.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for NOVARTIS AG-REG?

ChartMill assigns a fundamental rating of 7 / 10 to NOT.DE.


What is the valuation status of NOVARTIS AG-REG (NOT.DE) stock?

ChartMill assigns a valuation rating of 5 / 10 to NOVARTIS AG-REG (NOT.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for NOVARTIS AG-REG?

NOVARTIS AG-REG (NOT.DE) has a profitability rating of 9 / 10.


What is the expected EPS growth for NOVARTIS AG-REG (NOT.DE) stock?

The Earnings per Share (EPS) of NOVARTIS AG-REG (NOT.DE) is expected to decline by -0.14% in the next year.


Is the dividend of NOVARTIS AG-REG sustainable?

The dividend rating of NOVARTIS AG-REG (NOT.DE) is 6 / 10 and the dividend payout ratio is 55.91%.